A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Recruiting · Phase 2 · NCT06958536
Conditions: Crohn's Disease
At a glance
- Research payments reported, 2025
- $451,950
- U.S. investigators named
- 18
- Sites paid
- 17
- Planned or actual enrollment
- 99
About the trial
- Sponsor
- Sanofi
- Tested
- brivekimig (drug), Placebo (drug)
- Dates
- Started 2025-06-03; completion 2029-10-17
- Results posted
- Not yet
This is a phase 2, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.
From ClinicalTrials.gov, last updated 2026-11-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $451,950 in research payments for this study in 2025 (91 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Marwan G. Fakih, MD Medical Oncology · Duarte, CA
- Naveen Gara, M.D. Gastroenterology · San Diego, CA
- Kumaravel Perumalsamy, M.D. Gastroenterology · Lancaster, CA
- Christopher Lieu, MD Medical Oncology · Aurora, CO
- Michael D. Feldman, DO Family Medicine · Village Of Palmetto Bay, FL
- Vipin Gupta, MD Gastroenterology · Lighthouse Point, FL
- David Kerman, M.D. Gastroenterology · Miami, FL
- Muhammad A. Mohiuddin, M.D. Gastroenterology · Kissimmee, FL
- Aasim M. Sheikh, MD Gastroenterology · Marietta, GA
- Abdelaziz Elhaddad, MD Medical Oncology · Des Moines, IA
- Steven F. Polyak, MD Gastroenterology · Iowa City, IA
- Jessica R. Allegretti, M.D. Gastroenterology · Boston, MA
- Allan G. Coates, DO Gastroenterology · Wyoming, MI
- Patricia M. Lorusso, DO Medical Oncology · Detroit, MI
- Parakkal Deepak, MD Gastroenterology · Saint Louis, MO
- Millie D. Long, MD Internal Medicine · Chapel Hill, NC
- Adnan Ahmad, D.O. Gastroenterology · Camp Hill, PA
- William M. Pandak JR., M.D. Gastroenterology · Richmond, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Tropical Clinical Trials $53,685
- Central Florida Gastro Research Llc $46,076
- The Clinical Trials Network Llc $43,600
- Nursing Ce Trust Fund $42,922
- Gastroenterology and Liver Institute $41,136
- Washington University Division $33,126
- University of Iowa Hospital & Clinics, IA $31,141
- Gastroenterology Associates of West Michigan Plc West Michigan Clinical Research Center $29,700
- Gastroenterology Research of America Llc $27,419
- Yale University $24,218
- Brigham and Women's Hospital, MA $22,131
- Alliance Medical Research, Llc $14,407
- Gastrointestinal Specialists of Ga $13,472
- Mcguire Research Inst Inc Research Services 151 $11,983
- Multiple Doctors $9,290
- $5,046
- Regents of University of Coloradoschool of Medicine Attn S Pearson General Internal Medicine $2,048
- Exigent Research Llc $550
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.